Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension

Gastroenterology

Volumn 121, Issue 2, 2001, Pages 389-395

  Schepke, Michael ^a   Werner, Eva ^a   Biecker, Erwin ^a   Schiedermaier, Peter ^a   Heller, Jörg ^a   Neef, Markus ^a   Stoffel Wagner, Birgit ^a   Hofer, Ulrich ^a   Caselmann, Wolfgang H ^a   Sauerbruch, Tilman ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; CYSTATIN C; IRBESARTAN; RENIN; SERUM ALBUMIN; SODIUM;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMODYNAMICS; HUMAN; HYPOTENSION; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; VENOUS PRESSURE;

EID: 0034898990     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2001.26295     Document Type: Article

References (29)

1. The treatment of portal hypertension: A meta-analytic review
2. Propranolol - A medical treatment for portal hypertension?
3. Propranolol for prevention of gastrointestinal bleeding in patients with cirrhosis
4. Hemodynamic events in a prospective randomized clinical trial of propranolol versus placebo in the prevention of first variceal hemorrhage
5. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis
6. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices
7. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis
8. Effects of propranolol on azygos blood flow and hepatic and systemic hemodynamics in cirrhosis
9. Short-term effects of propranolol on portal venous pressure
10. Acute and chronic hemodynamic effects of propranolol in unselected cirrhotic patients
11. The effect of propranolol on portal hypertension in patients with cirrhosis: A hemodynamic study
12. Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis
13. Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis
14. Angiotensin II receptor antagonists in the pharmacological therapy of portal hypertension: A caution
15. Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension
16. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis
17. Transection of the esophagus for bleeding esophageal varices
18. Correlation of serum concentrations of cystatin C and creatinine to insulin clearance in liver cirrhosis
19. Comparison of portal vein velocity and the hepatic venous pressure gradient in assessing the acute portal hemodynamic response to propranolol in patients with cirrhosis
20. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis
21. Haemodynamic, renal sodium handling, and neurohumoral effects of acute administration of losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis
22. Sodium handling in patients with well compensated cirrhosis is dependent on the severity of liver disease and portal pressure
23. Angiotensin II induces contraction and proliferation of human hepatic stellate cells
24. The cellular pathogenesis of portal hypertension: Stellate cell contractility, endothelin and nitric oxide
25. An updated review on its use in cardiovascular disorders
26. An elective titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators
27. Efficiency of irbesartan, an angiotensin II receptor antagonist, on portal pressure and intrahepatic resistance in cirrhosis of the liver
28. Efficacy of irbesartan, an angiotensin II selective antagonist, in the treatment of portal hypertension
29. Effect of angiotensin II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin-aldosterone system in cirrhosis with ascites